Late type of the nasal allergic response. Review

Scripta Medica Facultatis Medicae Universitatis Brunensis Masarykianae

Volumn 74, Issue 5, 2001, Pages 303-344

  Pelikan, Z ^a  

^a Inst Med Sciences De Klokkenberg   (Netherlands)

Author keywords

Clinical; Immunological and pharmacological characteristics; Late nasal allergic response

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR STIMULATING AGENT; ALLERGEN; ASTEMIZOLE; BECLOMETASONE; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CETIRIZINE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLEMASTINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLIC AMP DERIVATIVE; ESTERASE; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G; IPRATROPIUM BROMIDE; KETOTIFEN; KININ; LEVOCABASTINE; LORATADINE; MEBHYDROLIN; NEDOCROMIL SODIUM; NEUROTOXIN; OXYPHENONIUM BROMIDE; TERFENADINE; UNINDEXED DRUG;

ALLERGIC REACTION; ALLERGIC RHINITIS; ANAMNESIS; BASOPHIL; BLEEDING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EDEMA; EOSINOPHIL; EOSINOPHILIA; EPITHELIUM CELL; FOOD INTAKE; GOBLET CELL; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; LEUKOCYTE COUNT; LYMPHOCYTE; NEUTROPHIL; NOSE ALLERGY; NOSE MUCOSA; NOSE OBSTRUCTION; NOSE PROVOCATION TEST; NOSE SECRETION; PRURITUS; REVIEW; RHINOMANOMETRY; SINUSITIS; SNEEZING;

EID: 0035735565     PISSN: 12113395     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Allergic and nonallergic rhinitis
2. The role of immediate, late and delayed reactions in allergic nasal disease
3. Provocation tests - A definitive confirmation of the role and involvement of a certain allergen or a non-specific hyperreactivity agent in the complaints of patients with an allergy disorder
4. Immediate hypersensitivity and non-specific hyperreactivity in the nose and bronchial tree - A possible double role of the mast cells and basophils, - The place and role of the chemicals
5. Classification of allergic reactions responsible for clinical hypersensitivity and disease
6. Late and delayed responses of the nasal mucosa to allergen challenge
7. Cytologic changes in the nasal secretions (NS) during the immediate (INR) and late nasal response (LNR) to allergen challenge (NPT)
8. Intracellular changes of eosinophils (EO), neutrophils (NE) and basophils (BS) in nasal secretions (NS) during the early (ENR) and late (LNR) nasal response
9. Late nasal response (LNR) - Its characteristics, feature and possible mechanism(s)
10. The effects of Disodium cromoglycate and Beclomethasone dipropionate on the immediate response of the nasal mucosa to allergen challenge
11. The effects of Disodium cromoglycate and Beclomethasone dipropionate on the late response of the nasal mucosa to allergen challenge
12. The effects of Disodium cromoglycate and Beclomethasone dipropionate on the delayed nasal mucosa response to allergen challenge
13. Nasal secretions (NS) cytology during the delayed nasal response to allergen challenge (DNR)
14. Role of nasal allergy in chronic maxillary sinusitis-diagnostic value of nasal challenge with allergen
15. Chronic sinusitis maxillaris (CSM) - The role of nasal allergy and the diagnostic value of echography and radiographs
16. A new disease - A nasal form of pigeon breeder's disease
17. The changes in the nasal secretion eosinophils during the immediate nasal response to allergen challenge
18. The role of the nasal mucosa in some cases of allergic conjunctivitis and the effects of Disodium cromoglycate (DSCG)
19. Nasal challenge with allergen in patients with secretory otitis media (SOM) and otalgia OL
20. Rhinitis and secretory otitis media: A possible role of food allergy
21. Changes in middle ear pressure (MEP) due to the nasal allergen challenge in patients with secretory otitis media (SOM) and otalgia (OL)
22. Disodium cromoglycate: Laboratory studies and clinical trial in allergic rhinitis
23. Induction of nasal late-phase reactions by insufflation of ragweed pollen extract
24. Nasal provocation: An approach to study the mediators of allergic and nonallergic rhinitis
25. Non-specific hyperreactivity (N-SH) and basic types of nasal response to allergen challenge in rhinitis patients
26. Effects of oral cromolyn on the nasal response due to foods
27. Cytologic changes in nasal secretions (NS) during the late nasal response (LNR) pretreated with Disodium cromoglycate (DSCG) and Beclomethasone dipropionate (BDA) or Budesonide (BSA)
28. Effects of Cetirizine (CZ) on the immediate (INR) and the late nasal response (LNR) and on the eosinophils in the nasal secretions (NS)
29. The effects of cromolyn (DSCG) and budesonide (BSA) on the late nasal response (LNR), changes in the cell count in the nasal secretions (NS) and their intracellular changes
30. Nasal response to food ingestion challenge
31. The Role of Allergies in Sinus Disease - Children & Adults
32. The influx of inflammatory cells into nasal washings during the late response to antigen challenge. Effect of systemic steroid pretreatment
33. The role of leukotriene B4 (LTB4) in human allergic late-phase reaction: Lack of LTB4 inhibition by systemic glucocorticosteroids
34. Late phase allergic reactions
35. Immunohistology of the nasal mucosa following allergen-induced rhinitis
36. Relationship between the early, late and rechallenge reaction to nasal challenge with antigen: Observation on the role of inflammatory mediators and cells
37. Inflammatory mediators in nasal secretions during early and late reactions
38. Nasal methacholine challenge: A test for the measurement of nasal reactivity
39. Non-specific hyperreactivity of the nasal mucosa (N-SH)-comparison of histamine and methacholine challenges in rhinitis patients
40. The asthmatic response [AR] induced by the allergic reaction originating primarily in the nasal mucosa
41. Nasal provocative testing
42. Cytological changes in the nasal secretions during the immediate nasal response (INR)
43. Cytological changes in the nasal secretions during the late nasal response (LNR)
44. Cytologic changes in the nasal secretions (NS) during the immediate (INR), late (LNR) and delayed nasal response (DYNR) to allergen challenge and their pharmacologic modulation by various drugs
45. Intracellular changes in some cell types in nasal secretions (NS) during the immediate (INR) and late (LNR) nasal response to allergen challenge
46. Histologic changes in the nasal mucosa during the immediate (INR), late (LAR) and delayed (DNR) nasal response to allergen challenge
47. Late nasal response to allergen challenge (LNR) - Cytologic changes in the nasal secretions (NS) and histologic changes in the nasal mucosa
48. The effects of Budesonide (BSA) and Beclomethasone dipropionate (BDA) on the late asthmatic response (LAR)
49. Concept of pathogenesis and possible mechanism(s) underlying the late phase reactions, focused on the late asthmatic response (LAR)
50. The effects of budesonide (BSA) on the late asthmatic response (LAR), administered before and at various points in time after allergen challenge
51. Effects of Cromolyn (DSCG), Nedocromil (NDS) and Budesonide (BSA) on the dual late asthmatic response (DLAR), administered before and after allergen challenge
52. The effect of a single dose of cromolyn [DSCG], beclomethasone dipropionate [BDA], budesonide [BUD], nedocromil sodium [NDS] and salbutamol [SBT] on the late asthmatic response [LAR] administered before and after allergen challenge
53. Inhibition of the late asthmatic response by nedocromil sodium administered more than two hours after allergen challenge
54. The effects of cromolyn (DSCG), Nedocromil (NS) and Budesonide (BUD) on the early (EAR) and the late (LAR) asthmatic response, inhaled before and after allergen challenge
55. The protective effects of cromolyn (DSCG) and budesonide (BUD) on the early (EAR) and the late (LAR) asthmatic response after a short- and long-term pretreatment
56. Local production of specific IgE antibodies in allergic rhinitis patients with negative skin tests
57. Effect of systemic steroids on eosinophils (EOS) and major basic protein (MBP) during nasal antigen challenge
58. Mediators release in nasal secretions after grass pollen challenge
59. Experimentally induced nasal allergic responses
60. Behavior and clinical relevance of histamine and leukotrienes C4 and B4 in grasspollen-induced rhinitis
61. Leukotriene B4 as a mediator of early and late reactions to antigen in humans: The effect of systemic glucocorticoid treatment in vivo
62. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells
63. The pathophysiology of rhinitis. V. Sources of protein in allergen-induced nasal secretions
64. Allergen induced cellular infiltration and late reactions in the upper respatory tract
65. The late nasal response, its clinical and immunologic features, possible mechanisms and pharmacologic modulation
66. Response of the nasal mucosa to allergen challenge measured by two different methods of rhinomanometry
67. Diagnostic value of acoustic rhinometry: Patients with allergic and vasomotor rhinitis compared with normal controls
68. Nasal resistance to respiratory airflow: A plethysmographic alternative to the face mask
69. Comparison of oscillation with three other methods for measuring nasal airways resistance
70. Response of nasal blood flow to neurohormones as measured by laser-Doppler velocimetry
71. Late nasal response to allergen challenge (LNR) - Clinical features and pharmacologic modulation
72. Immediate nasal response to allergen challenge (INR) - Cytologic changes in the nasal secretions (NS) and histologic changes in the nasal mucosa
73. Allergic and non-specific hyperreactivity (N-SH) component in patients with chronic rhinitis
74. Participation of allergy [ALL] and non-specific hyperreactivity [N-SH] components in rhinitis
75. Histamine (HS) in nasal secretions (NS) and its changes during the basic types of nasal response (NR) to allergen challenge
76. The concentrations of histamine in the blood plasma and their changes during the basic types of the nasal response to allergen challenge
77. Allergic conjunctivitis relationship to allergic rhinitis and the effects of Disodium cromoglycate (DSCG)
78. Middle ear response to the nasal allergen challenge in patients with secretory otitis media (SOM)
79. Studies on the allergic and non-allergic nasal inflammation
80. Viscosity and spinability of nasal secretions induced by different provocation tests
81. Basophil influx occurs after nasal antigen challenge, Effects of topical corticosteroid pretreatment
82. The immediate/early, late and delayed nasal response to allergen challenge, their occurrence and association with various ,,in vivo" and ,,in vitro" diagnostic parameters, other organsÖ responses, and their pharmacologic control
83. Effect of short-term systemic glucocorticosteroid treatment of human nasal mediator release after antigen challenge
84. Mediator release during nasal provocation
85. Allergen-induced increase of eosinophil cationic protein in nasal lavage fluid: Effect of the glucocorticosteroid budesonide
86. Inflammatory cell recruitment following allergen exposure
87. Late-phase Eustachian tube (ET) and nasal allergic responses associated with inflammatory mediator (IM) elaboration
88. Nasal response due to the food ingestion challenge and protective effects of oral Disodium cromoglycate (DSCG)
89. A comparison of double-blind and open techniques of food ingestion challenge upon recording of objective parameters
90. Protective effects of oral Cromolyn (DSCG) on migraine due to the adverse reactions to foods
91. The protective effects of oral cromolyn (DSCG) on the response the paranasal sinuses (PSR) to the food ingestion challenge (FICH)
92. The effects of oral disodium cromoglycate [DSCG] on the basic types of nasal response (NR) to food ingestion challenge (FICH) and accompanying cellular changes in nasal secretions (NS)
93. Protective effects of oral cromolyn (DSCG) on the arthritis (ART) complaints due to the adverse reactions to foods
94. Effects of intranasal budesonide (BUD) on the early (ENR) and late nasal response (LNR) to nasal challenge (NPT) with bird faeces extrects
95. Pharmacologic modulation of the cytologic changes in the nasal secretions (NS) accompanying the late nasal response [LNR]. I. Topically administered drugs
96. Pharmacologic modulation of the cytologic changes in the nasal secretions (NS) accompanying the late nasal response to allergen challenge [LNR]. II
97. Effects of oral H1-receptor antagonists on the late nasal response [LNR] to allergen challenge
98. Nasal cytology
99. Anti-allergic drugs and immunotherapy
100. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids
101. Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: Effect of systemic corticosteroids and relationship to eosinophil influx
102. The protective effects of intranasal Nedocromil sodium on the immediate [INR] and the late nasal response [LNR] to allergen challenge
103. Effects of Nedocromil Sodium (NDS) on the late nasal response to allergen challenge [LNR] and the accompanying cellular changes in the nasal secretions (NS)
104. Pharmacotherapy of rhinitis
105. Hypothesis on the contribution of late-phase allergic responses to the understanding and treatment of allergic diseases
106. Mechanisms of early and late asthmatic reactions
107. Immune complexes and allergic disease
108. Late asthmatic responses
109. Antibody and immune-complex-mediated allergic and inflammatory reactions
110. Complement as a mediator of inflammation
111. Complement-biologically active products
112. Immunoglobulins
113. The role of neuropeptides in inflammation
114. Neuropeptides in the respiratory tract
115. Neuropeptides in the respiratory tract
116. Late-phase IgE-mediated reactions
117. Effects of oral H1-receptor antagonists on the late nasal response (LNR) to allergen challenge
118. The late asthmatic response to allergen challenge-Part I
119. The late asthmatic response to allergen challenge-Part II